Information Provided By: 
Fly News Breaks for July 9, 2019
ITCI
Jul 9, 2019 | 07:25 EDT
RBC Capital analyst Brian Abrahams kept his Outperform rating on Intra-Cellular, saying the stock downside that followed FDA results from two phase 3 studies of lumateperone in bipolar depression was "excessive". The analyst notes that while study 401 did not demonstrate a meaningful separation from placebo, expectations were low and the "signals of activity" as well as the affirmed clean safety should offer "indirect support" for luma's potential in its other indications such as schizophrenia and depression.
News For ITCI From the Last 2 Days
ITCI
Apr 23, 2024 | 06:57 EDT
